a p -aminobenzoic acid bridge and a mono-/polyglutamate chain of variable length
18 The SYNERGY-NASH (A Study of Tirzepatide [LY3298176] in Participants With Nonalcoholic Steatohepatitis) trial, 19 a phase 2b dose-finding study, randomized 190 patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis to receive weekly injections of the GLP-1 and GIP dual agonist tirzepatide 5 mg, 10 mg, or 15 mg or placebo for 52 weeks
The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation, and indigestion), which are usually mild to moderate and dose-related
5.1 Probiotics and prebiotics Probiotics are live microorganisms that provide health benefits when consumed (Ng et al., 2009)
And why exceeding 50 mcg daily increases side effect risk without proportional benefit